Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Zoster vaccine: is newer better?

Michael R. Kolber and Tony Nickonchuk
Canadian Family Physician March 2019, 65 (3) 197;
Michael R. Kolber
Professor with the PEER (Patients, Experience, Evidence, Research) Group in the Department of Family Medicine at the University of Alberta in Edmonton.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tony Nickonchuk
Clinical pharmacist with Alberta Health Services in Peace River and Northwest Health Centres.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Clinical question

Is there a difference in efficacy between the new, recombinant zoster vaccine (RZV) and the live zoster vaccine (LZV)?

Bottom line

Recombinant zoster vaccine appears more efficacious than LZV. Over 3 years, RZV prevents 1 additional case of herpes zoster (HZ) for about every 40 patients treated compared with 1 for every 60 to 70 with LZV. Both vaccines decrease the risk of postherpetic neuralgia. Recombinant zoster vaccine is more expensive and requires 2 injections whereas LZV only requires 1.

Evidence

There were 2 industry-supported placebo-controlled RCTs of RZV in immunocompetent patients without previous zoster infection or vaccine.1,2 Authors calculated numbers needed to treat (NNTs) (assuming linear disease rates) at 3 years to indirectly compare to LZV.

  • Studies of efficacy against HZ showed the following:

    • -In adults older than 50 years (N = 15 411; mean age 62), 0.08% had HZ with RZV versus 2.7% with placebo (NNT of about 40).1 In a comparable live-vaccine RCT, the NNT was about 70.3,4

    • -In adults older than 70 years (N = 13 900; mean age 76), 0.4% of patients had HZ versus 3.5% with placebo (NNT of about 40).2 In a comparable live-vaccine RCT (patients ≥ 60 years), the NNT was about 60.5

  • Studies of postherpetic neuralgia showed the following:

    • -For all ages, RZV had an NNT of 333 at 3.8 years or 422 at 3 years.1,2 Live vaccine3,5 had an NNT of about 360.

    • -For those older than 70 years, RZV had an NNT of 3351,2 and LZV had an NNT of 260.5

  • Serious adverse events occurred in 1.1% of those who had RZV, 1.9% of those who had LZV, and 1.3% of those who had placebo.1,5

  • Limitations with RZV studies were that blinding was questionable.1,2 No head-to-head RCTs comparing LZVs and RZVs with clinical outcomes exist. No RCTs with clinical outcomes exist of patients who previously had any zoster vaccine or HZ.

Context

  • Recombinant zoster vaccine differs from LZV in that 2 doses, 2 to 6 months apart are needed for RZV versus 1 for LZV.6,7 Recombinant zoster vaccine costs about 40% more (about $250 vs $180 for LZV).8

  • Current recommendations in Canada9 are to offer RZV to patients 50 years or older who previously received LZV or previously had HZ. In the United States,7 in those aged 50 to 59 years, RZV is recommended regardless of zoster infection or vaccine history; in those older than 60 years, either vaccine is given.

  • Neither vaccine is recommended for pregnant patients.6,7,9 Recombinant zoster vaccine might be considered in immunocompromised patients.9

Implementation

Annual rates of HZ increase with age, from about 4 in 1000 in those aged 40 to 64 to about 7 in 1000 in those 65 and older.10 Postherpetic neuralgia develops in 5% to 30% of HZ patients and also increases with age.11 Risk of HZ recurrence ranges from 2% to 6%.11 Patients who are or will be immunocompromised have a higher baseline and recurrence risk and should be encouraged to be vaccinated with RZV.9 If vaccinating patients who have had HZ or have received LZV, wait 1 year.9 Indirect comparison suggests, compared with LZV, 112 patients would have to be vaccinated with RZV to prevent 1 additional case of HZ.12

Notes

Tools for Practice articles in Canadian Family Physician are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in Canadian Family Physician are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice{at}cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.

Footnotes

  • Competing interests

    None declared

  • The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Lal H,
    2. Cunningham AL,
    3. Godeaux O,
    4. Chlibek R,
    5. Díez-Domingo J,
    6. Hwang SJ,
    7. et al
    . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372(22):2087-96.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Cunningham AL,
    2. Lal H,
    3. Kovac M,
    4. Chlibek R,
    5. Hwang SJ,
    6. Díez-Domingo J,
    7. et al
    . Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375(11):1019-32.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Schmader KE,
    2. Levin MJ,
    3. Gnann JW Jr,
    4. McNeil SA,
    5. Vesikari T,
    6. Betts RF,
    7. et al
    . Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012;54(7):922-8.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kolber MR,
    2. Nickonchuk T
    . Zoster vaccine: zoster loster or imposter coster? Edmonton, AB: Tools for Practice; 2012. Available from: www.acfp.ca/wp-content/uploads/tools-for-practice/1482257389_2016updatedtfp77zostervaccine.pdf. Accessed 2018 Dec 3.
  5. 5.↵
    1. Oxman MN,
    2. Levin MJ,
    3. Johnson GR,
    4. Schmader KE,
    5. Straus SE,
    6. Gelb LD,
    7. et al
    . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352(22):2271-84.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Shingrix [product monograph]. Mississauga, ON: GlaxoSmithKline Inc; 2017.
  7. 7.↵
    1. Kim DK,
    2. Riley LE,
    3. Hunter P
    . Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older—United States, 2018. MMWR Morb Mortal Wkly Rep 2018;67(5):158-60.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Products and pricing on the Alberta Blue Cross drug price list. Edmonton, AB: ABC Benefits Corporation; 2018. Available from: www.ab.bluecross.ca/dbl/pdfs/ABCDPL_2018_06_05.pdf. Accessed 2018 Jun 20.
  9. 9.↵
    1. National Advisory Committee on Immunization
    . Updated recommendations on the use of herpes zoster vaccines. An Advisory Committee Statement (ACS). Ottawa, ON: Government of Canada; 2018. Available from: www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed 2018 Nov 3.
  10. 10.↵
    1. Queenan JA,
    2. Farahani P,
    3. Ehsani-Moghadam B,
    4. Birtwhistle RV
    . The prevalence and risk for herpes zoster infection in adult patients with diabetes mellitus in the Canadian Primary Care Sentinel Surveillance Network. Can J Diabetes 2017;42(5):465-9.
    OpenUrl
  11. 11.↵
    1. Kawai K,
    2. Gebremeskel BG,
    3. Acosta CJ
    . Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4(6):e004833.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Tricco AC,
    2. Zarin W,
    3. Cardoso R,
    4. Veroniki AA,
    5. Khan PA,
    6. Nincic V,
    7. et al
    . Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ 2018;363:k4029.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 65 (3)
Canadian Family Physician
Vol. 65, Issue 3
1 Mar 2019
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Zoster vaccine: is newer better?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Zoster vaccine: is newer better?
Michael R. Kolber, Tony Nickonchuk
Canadian Family Physician Mar 2019, 65 (3) 197;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Zoster vaccine: is newer better?
Michael R. Kolber, Tony Nickonchuk
Canadian Family Physician Mar 2019, 65 (3) 197;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Clinical question
    • Bottom line
    • Evidence
    • Context
    • Implementation
    • Notes
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Tools for Practice

  • Bronchodilators or inhaled corticosteroids for postinfectious cough
  • Intrauterine devices for menorrhagia
  • Topical treatments for anal fissure
Show more Tools for Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire